Q2 2025 Earnings Estimates for Bristol-Myers Squibb (NYSE:BMY) issued by Zacks Research

Bristol-Myers Squibb (NYSE:BMY – Free Report) – Investment analysts at Zacks Research upped their Q2 2025 earnings per share estimates for Bristol-Myers Squibb in a report issued on Friday, May 24th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of $1.78 per share for the quarter, up from their prior estimate of $1.77. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $0.59 per share. Zacks Research also issued estimates for Bristol-Myers Squibb’s Q4 2025 earnings at $1.77 EPS, FY2025 earnings at $6.97 EPS and Q1 2026 earnings at $1.54 EPS.

BMY has been the subject of a number of other research reports. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Thursday. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Redburn Atlantic cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, 6 February. Finally, Barclays reduced their price objective on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th . One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $60.00, according to MarketBeat.com.

See the latest stock report on BMY

Bristol-Myers Squibb trade down 0.7%

Shares of Bristol-Myers Squibb stock opened at $41.24 on Monday. Bristol-Myers Squibb has a 52-week low of $41.07 and a 52-week high of $66.46. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99, and a current ratio of 1.11. The stock has a market cap of $83.60 billion, a P/E ratio of -13.30, a PEG ratio of 13.96 and a beta of 0.45. The stock has a 50-day simple moving average of $47.80 and a 200-day simple moving average of $49.62.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s quarterly revenue was up 4.7% on a year-over-year basis. In the same quarter last year, the company earned $2.05 per share.

Institutional inputs and outputs

Several institutional investors have recently added to or reduced their stakes in the company. Capital International Investors grew its position in Bristol-Myers Squibb by 14.1% in the first quarter. Capital International Investors now owns 70,203,814 shares of the biopharmaceutical company’s stock valued at $3,807,153,000 after buying an additional 8,675,322 shares in the last quarter. Norges Bank purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at approximately $1,560,524,000. Northern Trust Corp grew its position in Bristol-Myers Squibb by 5.8% during the third quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after buying an additional 1,394,158 shares in the last quarter. Primecap Management Co. CA increased its position in Bristol-Myers Squibb by 14.6% during the fourth quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company’s stock valued at $1,207,549,000 after purchasing an additional 2,998,228 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Bristol-Myers Squibb by 7.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 16,959,807 shares of the biopharmaceutical company’s stock valued at $870,198,000 after purchasing an additional 1,246,066 shares during the last quarter. 76.41% of the shares are currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a $0.60 dividend. This represents an annualized dividend of $2.40 and a dividend yield of 5.82%. The ex-dividend date was Thursday, April 4. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

About Bristol-Myers Squibb

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read more

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.